



**University of  
Zurich<sup>UZH</sup>**

**Zurich Open Repository and  
Archive**

University of Zurich  
University Library  
Strickhofstrasse 39  
CH-8057 Zurich  
[www.zora.uzh.ch](http://www.zora.uzh.ch)

---

Year: 2015

---

**Response to Aghdassi et al., Letter to the editor "Genetic polymorphisms in the UDP-glucuronosyltransferase UGT1A7 gene in patients with acute liver failure after kava-kava consumption"**

Stickel, Felix

DOI: <https://doi.org/10.1007/s00204-015-1612-8>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-119317>

Journal Article

Accepted Version

Originally published at:

Stickel, Felix (2015). Response to Aghdassi et al., Letter to the editor "Genetic polymorphisms in the UDP-glucuronosyltransferase UGT1A7 gene in patients with acute liver failure after kava-kava consumption". Archives of toxicology, 89(11):2175-2176.

DOI: <https://doi.org/10.1007/s00204-015-1612-8>

Letter to Editor

## **Kava hepatotoxicity – role of genetic variation of UDP glucuronosyltransferase?**

Felix Stickel<sup>1</sup>

<sup>1</sup>Department of Gastroenterology and Hepatology, University Hospital of Zürich &  
Division of Hepatology, Clinic Beau-Site, Hirslanden Bern, Switzerland

Key words: kava, drug-induced liver injury, hepatitis, liver failure

Correspondence to

Felix Stickel, MD

Division of Hepatology

Clinic Beau-Site, Bern, Switzerland

Phone +41-31-335 7817

Fax +41-31-335 3519

Email [felix.stickel@ikp.unibe.ch](mailto:felix.stickel@ikp.unibe.ch)

Conflict of interest: none declared

**Sir,**

Diagnosis of drug-induced liver injury (DILI) due to herbal and dietary supplements (HDS) is notoriously difficult and often based on circumstantial evidence and exclusion of other causes. Risk factors are poorly defined and the spectrum of potential culprit products is changing continuously. Among the well-known precipitators of acute liver injury potentially causing liver failure are products derived from Kava (*Piper methysticum rhizoma*) previously used for the treatment of anxiety and depression. Over 100 cases of serious liver damage have been recorded worldwide, with numerous Kava products from different manufacturers and no obvious pattern with regard to mode of extraction, dosage, duration of intake, co-medication or patient characteristics. Following numerous cases of fulminant liver failure leading to liver transplantation and death, Kava products were banned in the United States, Europe and Australia (1). Although clinical presentation was considerably variable, causality assessment left little doubt that Kava was the cause in a majority of a series of 29 cases of adverse hepatic reactions due to Kava in Germany (2). Among these patients, nine developed fulminant liver failure with subsequent liver transplantation in eight of the patients, and three died eventually. Apart from the fact that the majority of individuals were women, likely reflecting consumers' preferences rather than true disposition, no apparent risk factor could be identified. Russmann and coworkers suggested a poor-metabolizer phenotype of cytochrome P450 2D6 as a risk factor for developing Kava-related liver damage (3), however, this observation has not made it into routine diagnostics to identify subjects at risk.

In this issue of the *Archives*, Aghdassi *et al.* present an interesting suggestion that there may be a possible additional degradation pathway, and genetic risk factor for Kava-related DILI related to the degradation of kavapyrones by a variation of the gene coding for uridine-

diphosphate (UDP)-glucuronosyltransferase, *UGT1A7\*3* (4). Authors genotyped 4 patients with fulminant hepatic failure following kava ingestion and found an *UGT1A7\*3* allele frequency of 37.5%, and 50% in those undergoing liver transplantation, but no CYP2D6 poor metabolizer phenotype. Considering the *UGT1A7\*3* allele frequencies among Caucasians between 16-36%, authors felt that the mild overrepresentation in their patients could be a hint for *UGT1A7\*3* as a genetic risk factor. In earlier studies, variant *UGT1A7\*3* was found in 43 of 59 patients with hepatocellular carcinoma studied by Vogel and co-workers (5), but this finding was later revised and attenuated after re-genotyping an enlarged cohort unravelled a PCR amplification bias (6). Although the idea is intriguing, several aspects call for caution in this regard: 1. With such low numbers, the presented series of 4 (!) patients may well be subject to a type I error detecting an association that does not exist; frankly speaking, the *UGT1A7\*3* allele frequency of 50% in transplant liver recipients may simply be a chance finding, and more patients need to be genotyped to generate robust data that withstand statistical scrutiny. For this, it would be interesting to see the *UGT1A7\*3* allele frequency in a larger series of patients with unequivocal kava-related liver injury, and networking with data bases maintained by international DILI networks is encouraged to find such patients (7, 8); 2. The *UGT1A7* isoenzyme is not expressed in the liver, which renders its importance for liver-related idiosyncratic drug reactions rather low, although it was suggested that may function as a gatekeeper for xenobiotics at their first entry into the human body; 3. Among the mutations in the *UGT* gene with a high prevalence in the population is that coding for Gilbert-Meulengracht hyperbilirubinemia, commonly not associated with DILI, but other misadventures. For example, genetic polymorphisms in *UGT1A1*, such as *UGT1A1\*28* in Caucasians and Asians and *UGT1A1\*6* only in Asians modify

the tolerability of irinotecan, resulting in severe neutropenia in homozygous carriers of one or heterozygosity of either variation (9).

In conclusion, there seems to be yet inconclusive evidence that genetic variations in the *UGT* gene have a significant share in the predisposition to Kava-related DILI until there is more supportive data. But there may be other genetic variants with a more significant impact, and efforts to their identification are clearly commendable.

And although Kava is thankfully off the market, other products are on the rise with unclear risk profiles and the potential to cause life-threatening liver injury (10). Attentive surveillance of their use remains an important task, and thrusting work-up of cases is warranted should toxicities occur.

## References

1. Centers for Disease Control and Prevention. Hepatic toxicity possibly associated with kava-containing products – United States, Germany, and Switzerland. *JAMA* 2003;289:36-37.
2. Stickel F, Baumüller HM, Seitz KH, et al. Hepatitis induced by Kava-Kava (*Piper methysticum rhizoma*). *J Hepatol* 2003;39:62-7.
3. Russmann S, Lauterburg BH, Helbling A. Kava hepatotoxicity. *Ann Intern Med* 2001;135:68-9.
4. Aghdassi AA, Kraft M, Domschke W, Lerch MM, Weiss FU. Genetic polymorphisms in the UDP-glucuronosyltransferase UGT1A7 gene in patients with acute liver failure after kava-kava consumption. *Arch Toxicol* 2015 (letter to editor).

5. Vogel A, Kneip S, Barut A, et al. Genetic link of hepatocellular carcinoma with polymorphisms of the UDP-glucuronosyltransferase UGT1A7 gene. *Gastroenterology*. 2001;121:1136–1144.
6. Vogel A, Ockenga J, Tukey RH, et al. Genotyping of the UDP-glucuronosyltransferase (UGT) 1A7 gene revisited. *Gastroenterology* 2011;140:1692-3.
7. Andrade RJ, Lucena MI, Fernandez MC, Pelaez G, Pachkoria K, Garcia-Ruiz E, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. *Gastroenterology* 2005;129:512–521.
8. Fontana RJ, Watkins PB, Bonkovsky HL, Chalasani N, Davern T, Serrano J, et al. Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. *Drug Saf* 2009;32:55–68.
9. Ichikawa W, Uehara K, Minamimura K, et al. An internally and externally validated nomogram for predicting the risk of irinotecan-induced severe neutropenia in advanced colorectal cancer patients. *Br J Cancer* 2015;112:1709-16.
10. Navarro VJ, Barnhart H, Bonkovsky HL, et al. Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. *Hepatology* 2014;60:1399-408.